If you have been reading about circadian rhythm and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-02. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
2 [Fe(EDTA)]− + H2S → 2 [Fe(EDTA)]2− + S + 2 H+ In this application, the iron(III) centre is reduced to its iron(II) derivative, which can then be reoxidised by air. In a similar manner, nitrogen oxides are removed from gas streams using [Fe(EDTA)]2−.
In July 2020, the US National Institutes of Health stated "There is insufficient evidence to recommend for or against using vitamin D supplementation for the prevention or treatment of COVID-19." In that same year, the UK National Institute for Health and Care Excellence (NICE) position was to not recommend to offer a vitamin D supplement to people solely to prevent or treat COVID-19. NICE updated its position in 2022 to "Do not use vitamin D to treat COVID-19 except as part of a clinical trial." Both organizations included recommendations to continue the previously established recommendations on vitamin D supplementation for other reasons, such as bone and muscle health, as applicable. Both organizations noted that more people may require supplementation due to lower amounts of sun exposure during the pandemic. Vitamin D deficiency and insufficiency have been associated with adverse outcomes in COVID-19. Supplementation trials, mostly large, single, oral dose upon hospital admission, reported lower subsequent transfers to intensive care and to all-cause mortality.
The UN Single Convention provided a legal framework, and in 1988, the Convention against Illicit Traffic expanded that framework, working the US-style punitive approach into international law. By the end of Reagan's presidency in 1989, illicit drugs were more readily available and cheaper than at the start of his first term in 1981.
Ions in a quadrupole field experience restoring forces that drive them back toward the center of the trap. The motion of the ions in the field is described by solutions to the Mathieu equation. When written for ion motion in a trap, the equation is
Sources: en.wikipedia.org
=== Historical definition === Sublimation is historically used as a generic term to describe a two-step phase transition – a solid-to-gas transition (sublimation in a more precise definition) followed by a gas-to-solid transition (deposition). (See below)
== June 2, 1915 (Wednesday) == Second Battle of Artois — The French bombarded German defenses around Neuville-Saint-Vaast, France for three days before launching an attack. Shabin-Karahisar uprising — An Armenian militia of 250 began a month-long resistance against the Ottoman Empire in response to the Armenian genocide using a fort in the Giresun Province of Turkey. Ceylon Governor Robert Chalmers declared martial law in the colony (now Sri Lanka) after violent unrest between Muslim and Buddhist broke out in Kandy and spread to other towns and cities. The Imperial German Army established the 83rd and 84th Infantry Divisions. Born: Walter Tetley, American voice actor, best known as the voice of "Sherman" in the TV cartoon Mr. Peabody; as Walter Campbell Tetzlaff, in New York City, United States (d. 1975) Lester del Rey, American science fiction writer and publisher, editor with wife Judy-Lynn del Rey of Del Rey Books; as Leonard Knapp, in Saratoga Township, Winona County, Minnesota, United States (d. 1993) Li Lili, Chinese actress, known for film roles in Little Toys and The Big Road; as Qian Zhenzhen, in Beijing, Republic of China (present-day China) (d. 2005) Died: George Randell, 84, Australian politician, Member of the Western Australian Legislative Council from 1873 to 1875 and 1880 to 1890 (b. 1830) Dave Orr, 55, American baseball player, first baseman for various teams including the New York Metropolitans and the Brooklyn Bridegrooms from 1883 to 1890 (b. 1859)
syncytium Also symplasm; pl. syncytia. A multinucleate cell, i.e. a cell containing more than one nucleus or, in the broadest sense, more than one nuclear genome (a meaning which is equated with polyploidy). Syncytia may form as a result of cell fusion between uninucleate cells, migration of a nucleus from one cell to another, or multiple nuclear divisions without accompanying cytokinesis (forming a coenocyte). The term may also refer to cells which are interconnected by specialized membranes with gap junctions as in some neuromuscular cell types.
Sources: en.wikipedia.org
Novichok (Russian: Новичо́к, lit. 'newcomer, novice, newbie') is a family of nerve agents, some of which are binary chemical weapons. The agents were developed at the GosNIIOKhT state chemical research institute by the Soviet Union and Russia between 1971 and 1993. Some Novichok agents are solids at standard temperature and pressure, while others are liquids. Dispersal of solid form agents is thought possible if in ultrafine powder state. Russian scientists who developed the nerve agents claim they are the deadliest ever made, with some variants possibly five to eight times more potent than VX, and others up to ten times more potent than soman. Iran has also been associated with the production of such chemical agents. In the twenty-first century, Novichok agents came to public attention after they were used to poison opponents of the Russian government, including in the attempted assassination of Sergei Skripal in the United Kingdom which resulted in the poisonings of 5 people and the death of an unrelated civilian in Amesbury (2018), as well as the poisoning of Alexei Navalny (2020). However, the use of Novichok domestically against Russian citizens has been known since at least 1995. In November 2019, the Organisation for the Prohibition of Chemical Weapons (OPCW), which is the executive body for the Chemical Weapons Convention (CWC), added the Novichok agents to "list of controlled substances" of the CWC "in one of the first major changes to the treaty since it was agreed in the 1990s" in response to the 2018 poisonings in the UK.
In an announcement that surprised some foreign experts, the joint investigation concluded that early transmission via the cold chain of frozen products was "possible". In March 2021, the WHO published a written report with the results of the study. The joint team stated that there are four scenarios for introduction:
Wilson pleaded no contest to the assault and was sentenced in 2010 to two years in prison. In 2017, when The Wolf of Wall Street producer Red Granite Pictures was involved in the 1Malaysia Development Berhad scandal, DiCaprio turned over the gifts he received from business associates at the production company, including from fugitive businessman Jho Low, to the US government. These included a Best Actor Oscar trophy won by Marlon Brando, a $3.2 million Pablo Picasso painting, and a $9 million Jean-Michel Basquiat collage.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.